Efficacy of Topical Corticosteroid Monotherapy in Inducing and Maintaining Clinical and Histologic Remission in Adolescent and Adult Patients with Eosinophilic Esophagitis: a Systematic Review and Meta-Analysis

Background: Eosinophilic esophagitis (EoE) is the second most common cause of esophagitis. Topical steroids represent a promising group of drugs for inducing and maintaining clinical and histological remission in these patients.
Objective. To evaluate the effectiveness of topical steroids in inducing and maintaining clinical and histological remission in adolescent and adult patients with EoE.
Methods. A systematic literature search using defined keywords was performed up to March 20, 2021 in the MEDLINE / PubMed, EMBASE (Excerpta Medica), and Cochrane Central Register of Controlled Trials, ClinicalTrial.gov databases.
Results. 390 patients from 5 studies were included in this systematic review with meta-analysis. The meta-analysis showed that topical steroids, compared with placebo, was more effective in inducing (odds ratio (OR) 75.77; 95 % confidence interval (CI): (21.8; 263.41), p < 0.001) and maintaining complete histological remission (OR 103.65; 95 % CI: (36.05; 298.01), p < 0.001) in patients with EoE. Also, topical steroids significantly relieved disease symptoms compared with placebo in inducing and maintaining clinical remission (OR 4.86; 95 % CI: (1.4; 16.86), p = 0.01) and (OR 11.06; 95 % CI: (4.62; 26.45), p < 0.001) respectively.
Conclusions. Topical steroids represent an effective group of drugs for inducing and maintaining histologic and clinical remission in adolescent and adult patients with EoE.

1. A. J. Lucendo et al., “Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults,” United Eur. Gastroenterol. J., vol. 5, no. 3, pp. 335–358, 2017, doi: 10.1177/2050640616689525.

2. E. S. Dellon and I. Hirano, “Epidemiology and Natural History of Eosinophilic Esophagitis,” Gastroenterology, vol. 154, no. 2, pp. 319-332.e3, 2018, doi: 10.1053/j.gastro.2017.06.067.

3. V. T. Ivashkin et al, "Clinical Recommendations of the Russian Gastroenterological Association on the Diagnosis and Treatment of Eosinophilic Esophagitis," vol. 28, no. 6, pp. 84-98, 2018.

4. P. Navarro, Á. Arias, L. Arias-González, E. J. Laserna-Mendieta, M. Ruiz-Ponce, and A. J. Lucendo, “Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies,” Aliment. Pharmacol. Ther., vol. 49, no. 9, pp. 1116–1125, 2019, doi: 10.1111/apt.15231.

5. W. E. de Rooij et al., “Emerging incidence trends of eosinophilic esophagitis over 25 years: Results of a nationwide register-based pathology cohort,” Neurogastroenterol. Motil., 2021, doi: 10.1111/nmo.14072.

6. T. S. Gunasekaran et al., “Comprehensive Comparison of Dysphagia Predominant Eosinophilic Esophagitis: With and Without Food Impaction,” SN Compr. Clin. Med., vol. 3, no. 10, pp. 2134–2140, 2021, doi: 10.1007/s42399-021-00889-1.

7. T. H. Taft, E. Kern, L. Keefer, D. Burstein, and I. Hirano, “Qualitative assessment of patient-reported outcomes in adults with eosinophilic esophagitis,” J. Clin. Gastroenterol., vol. 45, no. 9, pp. 769–774, 2011, doi: 10.1097/MCG.0b013e3182166a5a.

8. I. Hirano et al., “AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis,” Gastroenterology, vol. 158, no. 6, pp. 1776–1786, 2020, doi: 10.1053/j.gastro.2020.02.038.

9. A. R. Murali, A. Gupta, B. M. Attar, V. Ravi, and P. Koduru, “Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials,” J. Gastroenterol. Hepatol., vol. 31, no. 6, pp. 1111–1119, Jun. 2016, doi: 10.1111/jgh.13281.

10. N. Di Tan, Y. L. Xiao, and M. H. Chen, “Steroids therapy for eosinophilic esophagitis: Systematic review and meta-analysis,” J. Dig. Dis., vol. 16, no. 8, pp. 431–442, Aug. 2015, doi: 10.1111/1751-2980.12265.

11. E. S. Dellon et al., “Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis,” Gastroenterology, vol. 152, no. 4, pp. 776-786.e5, Mar. 2017, doi: 10.1053/j.gastro.2016.11.021.

12. T. Greuter et al., “Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients,” Clin. Gastroenterol. Hepatol., vol. 17, no. 3, pp. 419-428.e6, Feb. 2019, doi: 10.1016/j.cgh.2018.05.045.

13. T. Greuter et al., “Long-Term Treatment of Eosinophilic Esophagitis with Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept,” Am. J. Gastroenterol., vol. 112, no. 10, pp. 1527–1535, Oct. 2017, doi: 10.1038/ajg.2017.202.

14. T. Kuchen et al., “Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis,” Allergy Eur. J. Allergy Clin. Immunol., vol. 69, no. 9, pp. 1248–1254, 2014, doi: 10.1111/all.12455.

15. D. Moher et al., “Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement,” PLoS Medicine, vol. 6, no. 7. PLoS Med, Jul. 2009, doi: 10.1371/journal.pmed.1000097.

16. J. P. T. Higgins et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” BMJ, vol. 343, no. 7829, pp. 1–9, 2011, doi: 10.1136/bmj.d5928.

17. S. P. Hozo, B. Djulbegovic, and I. Hozo, “Estimating the mean and variance from the median, range, and the size of a sample,” BMC Med. Res. Methodol., vol. 5, pp. 1–10, 2005, doi: 10.1186/1471-2288-5-13.

18. A. Straumann et al., “Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis,” Gastroenterology, vol. 159, no. 5, pp. 1672-1685.e5, 2020, doi: 10.1053/j.gastro.2020.07.039.

19. J. A. Alexander et al., “Swallowed Fluticasone Improves Histologic but Not Symptomatic Response of Adults With Eosinophilic Esophagitis,” Clin. Gastroenterol. Hepatol., vol. 10, no. 7, pp. 742-749.e1, Jul. 2012, doi: 10.1016/j.cgh.2012.03.018.

20. A. Straumann et al., “Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis,” Gastroenterology, vol. 139, no. 5, pp. 1526-1537.e1, Nov. 2010, doi: 10.1053/j.gastro.2010.07.048.

21. A. J. Lucendo et al., “Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial,” Gastroenterology, vol. 157, no. 1, pp. 74-86.e15, Jul. 2019, doi: 10.1053/j.gastro.2019.03.025.

22. A. Straumann et al., “Long-Term Budesonide Maintenance Treatment Is Partially Effective for Patients With Eosinophilic Esophagitis,” Clin. Gastroenterol. Hepatol., vol. 9, no. 5, pp. 400–409, May 2011, doi: 10.1016/j.cgh.2011.01.017.

23. A. L. Lai, S. Girgis, Y. Liang, S. Carr, and H. Q. Huynh, “Diagnostic criteria for eosinophilic esophagitis: A 5-year retrospective review in a pediatric population,” J. Pediatr. Gastroenterol. Nutr., vol. 49, no. 1, pp. 63–70, Jul. 2009, doi: 10.1097/MPG.0b013e318184c917.

24. J. McElhiney et al., “The Mayo Dysphagia Questionnaire-30: Documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease,” Dysphagia, vol. 25, no. 3, pp. 221–230, 2010, doi: 10.1007/s00455-009-9246-8.

25. J. De Heer et al., “Histologic and Clinical Effects of Different Topical Corticosteroids for Eosinophilic Esophagitis: Lessons from an Updated Meta-Analysis of Placebo-Controlled Randomized Trials,” Digestion, 2020, doi: 10.1159/000507571.

26. S. S. Aceves, “Remodeling and fibrosis in chronic eosinophil inflammation,” Digestive Diseases, vol. 32, no. 1–2. S. Karger AG, pp. 15–21, 2014, doi: 10.1159/000357004.

27. E. Cheng, R. F. Souza, and S. J. Spechler, “Tissue remodeling in eosinophilic esophagitis,” American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 303, no. 11. Dec. 01, 2012, doi: 10.1152/ajpgi.00313.2012.